Skip to main content
NewslettersWatchlist

Biogen Inc(BIIB-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low198.97
Day High205.75
Open:198.97
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Why Biogen Stock Leaped Nearly 5% Higher Today
Barchart
Stocks Settle Mixed on Rising Bond Yields and Tech Strength
Motley Fool
Biogen (BIIB) Q1 2024 Earnings Call Transcript
Barchart
Stocks Give Up Early Gains and Close Lower as Chip Stocks Retreat
Barchart
Stocks Slide After U.S. Unemployment Report
Barchart
Stocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate Cuts
Barchart
5 Biotech Stocks With 26% Upside Potential or More
GlobeNewswire
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
GlobeNewswire
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
Motley Fool
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
GlobeNewswire
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
Barchart
Stocks Rebound as Bond Yields Fall on Dovish Fed Comments
Barchart
Stocks Slump as Hot U.S. CPI Report Dashes Fed Rate Cut Hopes
Motley Fool
Biogen (BIIB) Q4 2023 Earnings Call Transcript
Barchart
Stocks Slump as U.S. CPI Tops Forecasts
Barchart
S&P Futures Slip as Key U.S. Inflation Report Looms
GlobeNewswire
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
GlobeNewswire
Biogen to Realign Resources for Alzheimer's Disease Franchise
Barchart
Stocks Climb on Economic Optimism and Strong Tech Earnings
Barchart
Markets Today: Stock Index Futures Post Record Highs on Impressive Tech Earnings
Motley Fool
Highlights From the 2024 JPMorgan Health Care Conference
Motley Fool
These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall Street
Motley Fool
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
GlobeNewswire
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
GlobeNewswire
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
GlobeNewswire
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
Motley Fool
2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond
Motley Fool
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
Motley Fool
Biogen (BIIB) Q3 2023 Earnings Call Transcript
SYNDTGAM
Biogen cuts annual profit forecast on Alzheimer’s drug launch, deal costs
GlobeNewswire
Biogen Appoints Monish Patolawala to its Board of Directors
Baystreet
Light Week for Macroeconomic Numbers

Profile

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.